Abstract:It is long established that tumour-initiating cancer stem cells (CSCs) possess chemoresistant properties. However, little is known of the mechanisms involved, particularly with respect to the organisation of CSCs as stem-progenitor-differentiated cell hierarchies. Here we aimed to elucidate the relationship between CSC hierarchies and chemoresistance in an ovarian cancer model. Using a single cell-based approach to CSC discovery and validation, we report a novel, four-component CSC hierarchy based around the markers cluster of differentiation 10 (CD10) and aldehyde dehydrogenase (ALDH). In a change to our understanding of CSC biology, resistance to chemotherapy drug cisplatin was found to be the sole property of CD10−/ALDH− CSCs, while all four CSC types were sensitive to chemotherapy drug paclitaxel. Cisplatin treatment quickly altered the hierarchy, resulting in a three-component hierarchy dominated by the cisplatin-resistant CD10−/ALDH− CSC. This organisation was found to be hard-wired in a long-term cisplatin-adapted model, where again CD10−/ALDH− CSCs were the sole cisplatin-resistant component, and all CSC types remained paclitaxel-sensitive. Molecular analysis indicated that cisplatin resistance is associated with inherent- and adaptive-specific drug efflux and DNA-damage repair mechanisms. Clinically, low CD10 expression was consistent with a specific set of ovarian cancer patient samples. Collectively, these data advance our understanding of the relationship between CSC hierarchies and chemoresistance, which was shown to be CSC- and drug-type specific, and facilitated by specific and synergistic inherent and adaptive mechanisms. Furthermore, our data indicate that primary stage targeting of CD10−/ALDH− CSCs in specific ovarian cancer patients in future may facilitate targeting of recurrent disease, before it ever develops.

Cisplatin-resistant Osteosarcoma Cells Possess Cancer Stem Cell Properties in a Mouse Model

Cisplatin selects for stem-like cells in osteosarcoma by activating notch signaling.

Chloroquine Blocks The Autophagic Process In Cisplatin-Resistant Osteosarcoma Cells By Regulating The Expression Of P62/Sqstm1

Changes of stem cell properties in cisplatin-resistant osteosarcoma cells and its relationship with Notch signaling pathway

A Stem-like Patient-Derived Ovarian Cancer Model of Platinum Resistance Reveals Dissociation of Stemness and Resistance

Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line

Cancer Stem Cells in Osteosarcoma: Recent Progress and Perspective

Exosomal CTCF Confers Cisplatin Resistance in Osteosarcoma by Promoting Autophagy via the IGF2-AS/miR-579-3p/MSH6 Axis

Bio-inspired Cisplatin Nanocarriers for Osteosarcoma Treatment.

Targeting the CtBP1-FOXM1 transcriptional complex with small molecules to overcome MDR1-mediated chemoresistance in osteosarcoma cancer stem cells

Phenotypic Characterization of Drug Resistance and Tumor Initiating Cancer Stem Cells from Human Bone Tumor Osteosarcoma Cell Line Os-77

P-Glycoprotein Overexpression is Associated with Cisplatin Resistance in Human Osteosarcoma

Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.

Cisplatin Promotes Mesenchymal-Like Characteristics in Osteosarcoma Through Snail

Systemic Mesenchymal Stem Cells Reduce Growth Rate of Cisplatin-Resistant Ovarian Cancer.

Enrichment of Osteosarcoma Stem Cells by Chemotherapy

Doxorubicin induces enrichment of stem-like cells in osteosarcoma by activating Notch signaling

CD10−/ALDH− cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy

Targeting cancer stem cells by disulfiram and copper sensitizes radioresistant chondrosarcoma to radiation

Targeting of CXCR1 on Osteosarcoma Circulating Tumor Cells and Precise Treatment Via Cisplatin Nanodelivery

Multidrug Resistance and Tumor-Initiating Capacity of Oral Cancer Stem Cells.